-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-515989-14-00
4
2025-04-17
Nevoid Basal Cell Carcinoma Syndrome
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2024-516791-15-00
4
2025-04-08
Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2024-514845-12-00
4
2025-03-28
Non-Cystic Fibrosis Bronchiectasis
-
2024-515214-41-00
5
2025-03-27
advanced pancreatic cancer
-
2024-513862-20-00
5
2025-03-26
Chronic Rhinosinusitis with Nasal Polyposis
-
2024-513285-19-00
1
2025-03-14
Pancreatic Ductal Adeno Carcinoma
-
2024-515252-20-00
9
2025-03-14
Myelofibrosis (MF) unresponsive to JAK inhibitors
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2023-506288-33-00
9
2025-03-03
Metastatic castration resistant prostate cancer (mCRPC)
-
2023-508591-11-00
5
2025-02-25
Metastatic breast cancer
-
2024-514333-37-00
4
2025-02-25
Advanced Metastatic Ocular/Uveal Melanoma
-
2024-514306-31-00
5
2025-02-13
Pyoderma gangrenosum
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-513128-40-00
4
2025-02-06
Multifocal Motor Neuropathy
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo